Latest International Business News

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

ClearVue Technologies has secured A$6 million through a $5 million institutional placement and a fully underwritten $1 million Share Purchase Plan, aiming to bolster its balance sheet and fund international expansion and product development.

Resonance Health reports strong cash flow and progress in clinical trials, with a record forward order pipeline for its Software-as-a-Medical-Device business and profitable trial site clinics.

SPC Global Holdings Limited reported continued improvement in Q3 FY26, with net sales revenue and normalised EBITDA on track to meet full-year guidance. The company is progressing with its Mill Park facility closure and expanding its international footprint, particularly in Asia.

DUG Technology has resolved a US$2.1 million legal dispute with a supplier by agreeing to a US$1.5 million settlement, avoiding further court action without admitting liability.

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Acusensus Limited reported a robust 40% increase in revenue to $40.3 million for the half-year ended December 2025, driven by new contracts and international growth. However, the company recorded a substantial $20.8 million loss, largely due to a $16 million litigation settlement and strategic investments in future growth.

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

REA Group Ltd reported a solid 5% revenue increase for H1 FY26, driven by strong buyer demand and strategic AI integration, alongside announcing a $200 million on-market share buy-back.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.

Tigers Realm Coal continues to face significant delays in selling its Russian subsidiaries due to prolonged government approval processes and challenging market conditions. The company is exploring alternative strategies as operational risks mount.